Zymeworks Common Company Insiders

ZYME Stock  USD 12.72  0.21  1.62%   
About 83 percent of Zymeworks Common's insiders are selling. The analysis of the overall insider sentiment regarding Zymeworks Common Stock suggests that quite a large number of insiders are terrified. Zymeworks Common employs about 280 people. The company is managed by 26 executives with a total tenure of roughly 47 years, averaging almost 1.0 years of service per executive, having 10.77 employees per reported executive.
Ali Tehrani  CEO
President, Chief Executive Officer, Co-Founder, Director
Neil Klompas  President
Chief Financial Officer, Executive Vice President - Business Operations

Insider Sentiment 17

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2022-11-10Neil JosephsonDisposed 2475 @ 8.1View
2022-03-10Neil A KlompasDisposed 2979 @ 6.88View
2022-01-07Neil JosephsonAcquired 5000 @ 14.28View
2021-07-15Ali TehraniDisposed 3800 @ 36View
2021-07-12Ali TehraniDisposed 12669 @ 36.12View
2021-04-13James PriourDisposed 950 @ 27.93View
2021-03-15Kathryn O'driscollDisposed 786 @ 34.72View
2021-03-10Neil A KlompasDisposed 1425 @ 34.95View
2020-12-09Neil A KlompasDisposed 25000 @ 53.25View
2020-12-07Ali TehraniDisposed 850 @ 56.16View
2020-12-04Diana HausmanDisposed 6032 @ 55.12View
2020-12-02Diana HausmanDisposed 701 @ 55.01View
2020-11-02Ali TehraniDisposed 3500 @ 39.04View
2020-09-14Diana HausmanDisposed 40000 @ 45View
2020-04-03Ali TehraniAcquired 575 @ 33.39View
2020-01-27Troy CoxAcquired 7500 @ 46.5View
2019-05-06Neil A KlompasDisposed 8308 @ 19.23View
Monitoring Zymeworks Common's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zymeworks Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Zymeworks Common's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Zymeworks Common's future performance. Based on our forecasts, it is anticipated that Zymeworks will maintain a workforce of about 280 employees by April 2025.
 
Covid

Zymeworks Common Management Team Effectiveness

The company has return on total asset (ROA) of (0.1457) % which means that it has lost $0.1457 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3054) %, meaning that it created substantial loss on money invested by shareholders. Zymeworks Common's management efficiency ratios could be used to measure how well Zymeworks Common manages its routine affairs as well as how well it operates its assets and liabilities. As of March 23, 2025, Return On Tangible Assets is expected to decline to -0.0003. In addition to that, Return On Capital Employed is expected to decline to -0.0004. At present, Zymeworks Common's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 170.8 B, whereas Other Assets are forecasted to decline to about 30.9 M.
The current year's Net Income Applicable To Common Shares is expected to grow to about 117.5 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 46 M.

Zymeworks Common Workforce Comparison

Zymeworks Common Stock is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 6,272. Zymeworks Common holds roughly 280 in number of employees claiming about 4% of equities under Health Care industry.
The company has Profit Margin (PM) of (1.61) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.72) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.72.

Zymeworks Common Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zymeworks Common insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zymeworks Common's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Zymeworks Common insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-03-01
2.7
27
10
 3,050,023 
 261,099 
2024-09-01
1.0
1
1
 360,000 
 0.00 
2024-06-01
1.0
1
1
 74,000 
 0.00 
2024-03-01
1.0
12
12
 1,029,332 
 303,029 
2023-12-01
3.3333
10
3
 5,421,071 
 2,436 
2023-06-01
1.5
3
2
 3,450,000 
 0.00 
2023-03-01
4.0
12
3
 2,882,108 
 8,185 
2022-12-01
5.0
10
2
 316,847 
 8,360 
2022-03-01
2.5
10
4
 833,853 
 23,329 
2021-09-01
1.5
9
6
 64,794 
 116,420 
2021-06-01
1.0
8
8
 65,266 
 146,341 
2021-03-01
1.4375
23
16
 444,680 
 76,349 
2020-12-01
0.6875
11
16
 77,920 
 132,270 
2020-09-01
1.4
7
5
 41,132 
 80,000 
2020-06-01
10.0
10
1
 64,575 
 1,000.00 
2019-12-01
1.0
2
2
 127,500 
 137,500 
2019-06-01
1.0
8
8
 65,884 
 44,992 
2019-03-01
0.5333
8
15
 515,913 
 694,425 

Zymeworks Common Notable Stakeholders

A Zymeworks Common stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Zymeworks Common often face trade-offs trying to please all of them. Zymeworks Common's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Zymeworks Common's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Ali TehraniPresident, Chief Executive Officer, Co-Founder, DirectorProfile
Kenneth GalbraithChairman of the Board, President, Chief Executive OfficerProfile
Christopher AstleChief Financial Officer, Senior Vice PresidentProfile
Neil KlompasChief Financial Officer, Executive Vice President - Business OperationsProfile
Leone MBAEVP CFOProfile
Thomas KreudensteinDirector EngineeringProfile
Nina WeisserDirector TherapeuticsProfile
Lota ZothLead Independent DirectorProfile
Shrinal InamdarDirector RelationsProfile
Daniel JDCorporate VPProfile
Jack SpinksAssociate RelationsProfile
Neil MDChief OfficerProfile
Mark HollywoodExecutive OperationsProfile
Neil JosephsonInterim Chief Medical OfficerProfile
Anthony PolverinoExecutive Vice President - Early Development, Chief Scientific OfficerProfile
Paul MooreChief OfficerProfile
Diana PapoveSenior CommunicationsProfile
Jeffrey MDExecutive OfficerProfile
Diana HausmanChief Medical OfficerProfile
Ryan DerchoSenior AffairsProfile
Kenneth CACEO ChairmanProfile
Lindsey BScVice DevelopmentProfile
Josemund MBBSManaging PacificProfile
Laura OConnorHead ResourcesProfile
John FannSenior SciencesProfile
David PoonVP ManagementProfile

About Zymeworks Common Management Performance

The success or failure of an entity such as Zymeworks Common Stock often depends on how effective the management is. Zymeworks Common management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Zymeworks management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Zymeworks management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Please note, the presentation of Zymeworks Common's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Zymeworks Common's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Zymeworks Common's management manipulating its earnings.

Zymeworks Common Workforce Analysis

Traditionally, organizations such as Zymeworks Common use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Zymeworks Common within its industry.

Zymeworks Common Manpower Efficiency

Return on Zymeworks Common Manpower

Revenue Per Employee272.5K
Revenue Per Executive2.9M
Net Loss Per Employee438.2M
Net Loss Per Executive4.7B
Working Capital Per Employee757.7K
Working Capital Per Executive8.2M

Complementary Tools for Zymeworks Stock analysis

When running Zymeworks Common's price analysis, check to measure Zymeworks Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zymeworks Common is operating at the current time. Most of Zymeworks Common's value examination focuses on studying past and present price action to predict the probability of Zymeworks Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zymeworks Common's price. Additionally, you may evaluate how the addition of Zymeworks Common to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
CEOs Directory
Screen CEOs from public companies around the world
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Share Portfolio
Track or share privately all of your investments from the convenience of any device